Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)

• ClinicalTrials.gov Identifier: NCT04452591
• Recruitment Status: Recruiting
• First Posted: June 30, 2020
• Last Update Posted: April 30, 2024
• Sponsor: CG Oncology, Inc.
• Information provided by (Responsible Party): CG Oncology, Inc.

Tracking Information

• First Submitted Date: June 26, 2020
• First Posted Date: June 30, 2020
• Last Update Posted Date: April 30, 2024
• Actual Study Start Date: October 27, 2020
• Estimated Primary Completion Date: December 24, 2027 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 29, 2024)

• Cohort C: [ Time Frame: 36 months ]
  To determine the Complete Response rate at any time in patients with BCG-unresponsive CIS with or without concomitant HG Ta/T1 papillary disease.
• Cohort P: [ Time Frame: 36 months ]
  To determine the high-grade EFS of cretostimogene in patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS.Ta/T1 papillary disease without CIS.

Original Primary Outcome Measures (submitted: June 29, 2020)

Complete response rate in patients with carcinoma in situ (with or without concomitant high-grade Ta or T1 papillary disease) [ Time Frame: 24 months ]

Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.

Current Secondary Outcome Measures (submitted: April 29, 2024)

• Cohort C: Duration of response (DOR) [ Time Frame: 36 months ]
  Median duration of response in patients with a CR or PR in subjects
• Cohort C and Cohort P: Assess high-grade reoccurrence free survival (RFS) [ Time Frame: up to 60 months ]
• Cohort C and Cohort P: Assess progression free survival (PFS ) [ Time Frame: up to 60 months ]
• Cohort C:Complete Response rate at 12 months [ Time Frame: 12 months ]
• Cohort C and Cohort P : Cystectomy free survival [ Time Frame: up to 60 months ]
• Cohort C and Cohort P: Evaluate the safety of Cretostimogene [ Time Frame: 36 months ]
• Cohort C: Assess overall survival [ Time Frame: up to 60 months ]
• Cohort C: Reoccurrence free survival [ Time Frame: up to 60 months ]

Original Secondary Outcome Measures (submitted: June 29, 2020)

• Median Duration of response (DOR) [ Time Frame: 24 months ]
  Median duration of response in patients with a CR or PR in subjects
• Median progression free survival [ Time Frame: 24 months ]
  Median duration of progression free survival of subjects
• Time to tumor progression (TTP) [ Time Frame: 24 months ]
  Median time until patient disease progression (PD) in subjects
• Incidence of adverse events when CG0070 administered alone. [ Time Frame: 24 months ]
  Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0.
• Comparison of complete response in patients with persistent disease versus relapsed disease at baseline. [ Time Frame: 24 months ]
  Percentage in CR

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
• Official Title: A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

Brief Summary

This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment.

Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer.

Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment

Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC

Detailed Description

Cohort C(All Countries) :

An open-label trial designed to evaluate Cretostimogene + DDM in patients with NMIBC who have failed prior BCG therapy. Single treatment arm that enrolled 115 patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease

BCG failure is defined as a persistent or recurrent disease within 12 months of completion of adequate BCG therapy.

Cohort P(Japan and the United States Only):

To determine the all-cause High Grade Event Free Survival (HG-EFS) of cretostimogene in up to 75 patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS.

BCG failure is defined as a persistent or recurrent disease within 6 months of completion of adequate BCG therapy.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Non Muscle Invasive Bladder Cancer
• High-grade Ta/ T1 Papillary Disease Bladder Cancer

Intervention

• Biological: Cretostimogene Grenadenorepvec
  Engineered Oncolytic Adenovirus
• Other: n-dodecyl-B-D-maltoside
  Transduction-enhancing agent.
  Other Name: DDM

Study Arms

• Experimental: Cohort C(All Countries):Enrollment Closed
  Patients with CIS with or without HG Ta/T1 papillary disease. Cretostimogene will be administered intravesically following a series of bladder washes with 5% DDM and normal saline. Cretostimogene will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has disease recurrence at Week 13, they will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 then the patient will receive 3 weekly treatments. Cohort C(All Countries):Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 51 then every 6 months and then a last treatment at Weeks 73, 74, and 75 until the tumor returns or study treatment is completed at Week 97. Cohort C Extension( Japan and the US) At Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 51 then every 6 months starting at Weeks 73, 74, and 75 through Weeks 157, 158, and 159 until the tumor returns or study treatment is completed at Week 159.
  Interventions:

  • Biological: Cretostimogene Grenadenorepvec
  • Other: n-dodecyl-B-D-maltoside
• Experimental: Cohort P(Japan and United States Only) :Open to Enrollment

  HG Ta/T1 papillary disease bladder cancer patients.

  In Cohort P, cretostimogene will be administered at a dose of 1 × 1012vp IVE following instillation of 5% DDM. Cretostimogene will be administered every week for 6 treatments on Weeks 1, 2, 3, 4, 5, and 6. If the patient has recurrence at Week 13 or any timepoint, the patient will receive a second induction of 6 weekly treatments (Weeks 13, 14, 15, 16, 17, and 18.). If the tumor has not returned they will receive 3 weekly treatments every 12 weeks (approximately 3 months) starting Weeks 13, 14, and 15 through Week 51 (approximately 12 months), and then every 6 months starting at Weeks 73, 74, and 75 (approximately 18 months) through Month 36.

  Interventions:

  • Biological: Cretostimogene Grenadenorepvec
  • Other: n-dodecyl-B-D-maltoside

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: April 29, 2024): 190
• Original Estimated Enrollment (submitted: June 29, 2020): 110
• Estimated Study Completion Date: December 24, 2029
• Estimated Primary Completion Date: December 24, 2027 (Final data collection date for primary outcome measure)

Eligibility Criteria

Cohort C Inclusion Criteria

In order to be eligible for participation in this trial, the patient must:

• Be ≥18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.
• Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Have pathologically confirmed (WHO grading system employed for tumor grading) (Compérat 2019) BCG unresponsive CIS. Patients with BCG unresponsive CIS are those unlikely to benefit from, and who will not be receiving, further intravesical BCG. There is no maximum limit to the amount of prior BCG treatment, but maintenance BCG should be administered on a schedule consistent with standard induction-maintenance protocols (e.g., BCG weekly × 6 then weekly × 3 weeks administered at Months 3, 6, 12, 18, 24, and 36). Specifically, the definition of BCG unresponsive CIS will also require the following:

  • Pathologically confirmed relapsed or persistent CIS (with or without HG Ta or HG T1 disease) within 12 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).
  • Completion of qualifying BCG treatment (e.g., "5+2" minimum exposure) within 12 months of the initial qualifying dose of BCG (e.g., induction and initial maintenance or re-induction cycle must be completed over no more than a 12-month period of time).
  • Pathological confirmation of BCG unresponsive CIS within 8 weeks of study enrollment.
  • CIS specimen must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.
  • No maximum limit to the amount of BCG administered but maintenance BCG should be administered on a schedule consistent with the SWOG 8507 regimen (Lamm 2000).
• Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment (e.g., prior to Day 1 treatment).
• Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.
• Demonstrate adequate organ function
• Patients must be willing to comply with study mandated cystoscopies, urine cytology, urograms, biopsies, and other procedures (including TURBT or other resection for all Ta/T1 disease) for the duration of the study. Patients who withdraw consent for these procedures will be withdrawn from the trial

Cohort P Inclusion Criteria

• Be ≥18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent
• Have ECOG performance status of 0 to 2.

• Have pathologically confirmed (WHO grading system employed for tumor grading) (Compérat 2019) BCG-unresponsive HG Ta/T1 papillary disease without CIS. Patients with BCG-unresponsive HG Ta/T1 papillary disease are those unlikely to benefit from and who will not be receiving further IVE BCG. There is no maximum limit to the amount of prior BCG treatment, but maintenance BCG should be administered on a schedule consistent with standard induction-maintenance protocols. Specifically, the definition of BCG unresponsive HG Ta/T1 papillary disease without CIS will also require the following:

  • Pathologically confirmed recurrent HG Ta/T1 papillary disease without CIS within 6 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).
  • Patients with HG Ta: Completion of qualifying BCG treatment (e.g., "5+2" minimum exposure) within 12 months of the initial qualifying dose of BCG (e.g., induction and initial maintenance or re-induction cycle must be completed over no more than a 12-month period of time).
  • Patients with HG T1: Patients may be eligible after the initial induction alone (5 of 6 doses of an induction course) as the qualifying BCG treatment.
  • Completion (last dose) of qualifying BCG treatment within 12 months of study enrollment.
  • Pathological confirmation of BCG-unresponsive HG Ta/T1 papillary disease without CIS within 8 weeks of study enrollment.
  • All pathology specimens must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.
  • No maximum limit to the amount of BCG administered; however, there should be no more than 12 months between cycles of BCG
• Have all Ta and/or T1 disease resected, prior to study treatment (e.g., prior to Day 1 treatment).
• Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.
• Demonstrate adequate organ function,
• Patients must be willing to comply with study-mandated cystoscopies, urine cytology, imaging, biopsies, and other procedures for the duration of the trial

Cohort C and Cohort P Key Exclusion Criteria:

• Has current or past history of muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer.
• Any HGUC as T1, HG Ta, or CIS in the upper genitourinary tract or prostatic urethra (including CIS of the urethra) within 24 months prior to enrollment OR any history of T2 or higher stage urothelial carcinoma in the upper genitourinary tract (kidneys, renal collecting systems, ureters).
• Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of Day 1.
• Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.
• Has any of the following within the 6 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, pulmonary embolus, uncontrolled hypertension, or uncontrolled congestive heart failure.
• Cannot tolerate study-related biopsies, IVE administration, or 1-hour bladder hold of cretostimogene.
• IVE therapy within 8 weeks prior to beginning study treatment with the exception of cytotoxic agents (e.g., Mitomycin C, gemcitabine, doxorubicin and epirubicin) when administered as a single instillation immediately following a TURBT procedure which is permitted 14 or more days prior to beginning study treatment

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: JoAnn Horn; 516-456-1415; joann.horn@CGoncology.com

• Listed Location Countries: Australia, Japan, Korea, Republic of, Taiwan, United States

Administrative Information

• NCT Number: NCT04452591
• Other Study ID Numbers: CG3002S
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: CG Oncology, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: CG Oncology, Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: CG Oncology; CG Oncology

• PRS Account: CG Oncology, Inc.
• Verification Date: April 2024